News

Treatment with Novartis’ Cosentyx (secukinumab) significantly reduced disease activity compared to placebo in patients with non-radiographic axial spondyloarthritis (nr-axSpA), according to new data from the Phase 3 PREVENT trial. The trial achieved its primary endpoint (goal) of Assessment of Spondyloarthritis International Society response criteria (ASAS40) — defined as…

People with ankylosing spondylitis (AS) are at a greater risk of developing certain inflammatory diseases — specifically, Behcet’s disease, Buerger’s disease, acute anterior uveitis, sarcoidosis, and psoriasis, according to a Taiwanese study. The study, “Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing…

Moxibustion, a form of heat therapy widely used in East Asia, given in combination with conventional treatments may be of benefit to people with ankylosing spondylitis, at least in the short-term, a study reported. Benefits, mostly patient reported after a four-week treatment, included better physical function and health-related quality of…

Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told Bionews Services, publisher…

Depression is more common among people with ankylosing spondylitis (AS) than in the general population, with about a third of patients experiencing depressive symptoms, a meta-analysis reveals. The study, “Prevalence of Depression in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis,” was published in the…

Treatment with Novartis’ Cosentyx (secukinumab) led to a significant reduction in disease activity compared to placebo in patients with non-radiographic axial spondyloarthritis (nr-axSpA), according to results from the ongoing Phase 3 PREVENT trial. Novartis announced that Cosentyx achieved its 16-week primary endpoint as well as all secondary endpoints. Moreover, Cosentyx’s favorable…

A specific type of MRI called diffusion-weighted imaging is sensitive enough to identify patients with early signs of axial spondyloarthritis, a study has f0und. Results of the study, “Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis,” were published in…

Treating ankylosing spondylitis (AS) patients with Humira (adalimumab) or a potential biosimilar called IBI303 had comparable effects in reducing disease activity and improving quality of life, and showed a similar safety profile, according to a Phase 3 trial in China. The study, “IBI303, a biosimilar…

Baduanjin qigong training, a traditional Chinese exercise, may reduce fatigue and morning stiffness in people with ankylosing spondylitis (AS), according to a recent pilot study. The results, “A 12-week Baduanjin Qigong exercise improves symptoms of ankylosing spondylitis: A randomized controlled trial,” were published in the journal…

Eli Lilly‘s Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis. Taltz is a biological therapy, or a biological disease-modifying antirheumatic drug (bDMARD), that blocks…